1
|
Kast K, Rhiem K, Larsen M, Wappenschmidt B, Schmutzler R. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne. Cancer Med 2024; 13:e6920. [PMID: 38230850 PMCID: PMC10905677 DOI: 10.1002/cam4.6920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 12/07/2023] [Accepted: 12/31/2023] [Indexed: 01/18/2024] Open
Abstract
PURPOSE Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are associated with the Li-Fraumeni syndrome (LFS), and thus, surveillance and preventive measures are important for TP53 PV carriers. However, the penetrance of TP53 PVs can be low if the Chompret criteria are not fulfilled. In this study, we compared the phenotypic characteristics of families that did and did not fulfill the LFS criteria according to Chompret. METHODS The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) database was used to identify index patients with a likely pathogenic/pathogenic TP53 variant and their family members. The study investigated the type of variant, pedigree, age of onset, number of primary tumors, and histological type of BC. RESULTS TP53 PV were present in the index cases of 35 families, 57% (20/35) of which fulfilled the Chompret criteria. The median age of onset at first BC diagnosis was lower in families that fulfilled the Chompret criteria compared to those who did not. Four of all diseased individuals were minors (4%; 4/105) when malignancy was first diagnosed. Sarcomas and brain tumors occurred in 10% (10/105) and in 7% (7/105) of all diseased persons, respectively. BC was the most frequently occurring first tumor (60%; 62/105) and additional malignancy (45%; 20/44) in this cohort. Subsequent malignancies developed in 31% (20/65) of the individuals who fulfilled the Chompret criteria compared with 15% (6/40) of those who did not. CONCLUSION The tumor spectrum and age of onset found in this study showed that tumors other than BC had low disease penetrance in TP53 PV carriers identified using the GC-HBOC criteria for genetic testing.
Collapse
Affiliation(s)
- K. Kast
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - K. Rhiem
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - M. Larsen
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - B. Wappenschmidt
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| | - R. Schmutzler
- Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical FacultyUniversity Hospital CologneCologneGermany
| |
Collapse
|
2
|
Herold N, Bredow K, Hahnen E, Wappenschmidt B, Hauke J, Wiedemann R, Waha A, Blümcke B, Portnicki M, Pohl-Rescigno E, Rhiem K, Kast K, Hübbel V, Maringa M, Crombach G, Schmutzler R. Wissen-generierende Versorgung am Beispiel des erblich bedingten Mamma- und Ovarialkarzinoms (BC/OC): Evaluation des flächendeckenden Versorgungskonzepts. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- N Herold
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - K Bredow
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - E Hahnen
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - B Wappenschmidt
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - J Hauke
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - R Wiedemann
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - A Waha
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - B Blümcke
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - M Portnicki
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - E Pohl-Rescigno
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - K Rhiem
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - K Kast
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - V Hübbel
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - M Maringa
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - G Crombach
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| | - R Schmutzler
- Zentrum Familiärer Brust- und Eierstockkrebs, Centrum für Integrierte Onkologie (CIO), Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln
| |
Collapse
|
3
|
Herold N, Wappenschmidt B, Markiefka-Schömig B, Driesen J, Keupp K, Kröber S, Hahnen E, Carrizo K, Lampe B, Schmutzler R, Rhiem K. SMARCA4- Risikogen für das kleinzellige Ovarialkarzinome des hyperkalzämischen Typs (SCCOHT). Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Herold
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - B Wappenschmidt
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | | | - J Driesen
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Keupp
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - S Kröber
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - E Hahnen
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Carrizo
- Kaiserswerther Diakonie/Florence Nightingale Krankenhaus, Düsseldorf, Deutschland
| | - B Lampe
- Kaiserswerther Diakonie/Florence Nightingale Krankenhaus, Düsseldorf, Deutschland
| | - R Schmutzler
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Rhiem
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| |
Collapse
|
4
|
Herold N, Lichtenheldt F, Richters L, Wappenschmidt B, Hahnen E, Rhiem K, Schmutzler R. Erkrankungsrisiken und Lebensqualität nach prophylaktischer Mastektomie bei BRCA1/2 Mutationsträgerinnen. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Herold
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - F Lichtenheldt
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - L Richters
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - B Wappenschmidt
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - E Hahnen
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - K Rhiem
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| | - R Schmutzler
- Zentrum familiärer Brust- und Eierstockkrebs, Center for Integrated Oncology (CIO) Universitätsklinik Köln, Köln, Deutschland
| |
Collapse
|
5
|
Bülow L, Keupp K, Richters L, Pohl E, Wappenschmidt B, Zarghooni V, Reichstein-Gnielinski S, Maringa M, Giesecke J, Rhiem K, Hahnen E, Schmutzler R. Abstract P3-09-03: Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation – The origin of a constitutional mutation in a breast cancer family. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-09-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mosaicisms arise when specific cells within a developing organism mutate to result in two or more cell populations with distinct genotypes. In cases of gonosomal mosaicism a genetic variation is present in both somatic and germline cells.
Here, we describe a large Turkish breast cancer family with four affected individuals. In the Index patient (II-1; age of onset 45 years), a heterozygous deleterious frameshift mutation, c.1310dupA, p.His437Glnfs*2 in BRCA1 was identified using the TruRisk® gene panel designed by the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Predictive genetic testing showed heterozygous carrier status in the daughter (III-1).
The mutation was also analyzed in peripheral blood of the affected mother (I-1; age of onset 45 years) of the index patient by Sanger Sequencing. Interestingly, Sanger sequence did demonstrate the presence of remarkable small peaks presenting the frameshift mutation similar to a mosaic pattern. A second and third independent blood draw within a time frame of four month was tested and a mosaic signal of approximately 10 % was reproducibly detected.
In order to exclude a potential allelic drop out, independent sequencing experiments via next generation sequencing (NGS; TruRisk® gene panel) were performed. Again, the mutation was present with an allele read frequency of 12 %. No other pathogenic mutations were detected in any of the other tested breast cancer susceptibility genes.
To further examine and underscore the presence of gonosomal mosaicism different tissues should be analyzed. As no tumor material or surrounding normal breast tissue was available primary skin fibroblasts were isolated from skin biopsy. Sequencing of cultured primary fibroblasts demonstrated the absence of the familial BRCA1 mutation. With NGS-based CNV analysis as well as MLPA analysis we excluded aberrant copy numbers of BRCA1 in blood and fibroblasts.
In conclusion, our data provide striking evidence for a BRCA1 mosaicism, which is not detectable in all body cells. Due to the inheritance of the BRCA1 mutation to the next generations (II-1 and III-1), we assume the presence of a gonosomal mosaicism in the affected mother (I-1).
Additionally, the history of breast cancer onset in the family indicates that the BRCA1 mosaic mutation carrier do not necessarily have a milder phenotype compared to full heterozygotes. In this context our results implicate the importance of using highly sensitive sequencing platforms in routine diagnostics to ensure the detection of disease causing low-level mosaic mutations.Mosaicisms arise when specific cells within a developing organism mutate to result in two or more cell populations with distinct genotypes. In cases of gonosomal mosaicism a genetic variation is present in both somatic and germline cells.
Here, we describe a large Turkish breast cancer family with four affected individuals. In the Index patient (II-1; age of onset 45 years), a heterozygous deleterious frameshift mutation, c.1310dupA, p.His437Glnfs*2 in BRCA1 was identified using the TruRisk® gene panel designed by the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Predictive genetic testing showed heterozygous carrier status in the daughter (III-1).
The mutation was also analyzed in peripheral blood of the affected mother (I-1; age of onset 45 years) of the index patient by Sanger Sequencing. Interestingly, Sanger sequence did demonstrate the presence of remarkable small peaks presenting the frameshift mutation similar to a mosaic pattern. A second and third independent blood draw within a time frame of four month was tested and a mosaic signal of approximately 10 % was reproducibly detected.
In order to exclude a potential allelic drop out, independent sequencing experiments via next generation sequencing (NGS; TruRisk® gene panel) were performed. Again, the mutation was present with an allele read frequency of 12 %. No other pathogenic mutations were detected in any of the other tested breast cancer susceptibility genes.
To further examine and underscore the presence of gonosomal mosaicism different tissues should be analyzed. As no tumor material or surrounding normal breast tissue was available primary skin fibroblasts were isolated from skin biopsy. Sequencing of cultured primary fibroblasts demonstrated the absence of the familial BRCA1 mutation. With NGS-based CNV analysis as well as MLPA analysis we excluded aberrant copy numbers of BRCA1 in blood and fibroblasts.
In conclusion, our data provide striking evidence for a BRCA1 mosaicism, which is not detectable in all body cells. Due to the inheritance of the BRCA1 mutation to the next generations (II-1 and III-1), we assume the presence of a gonosomal mosaicism in the affected mother (I-1).
Additionally, the history of breast cancer onset in the family indicates that the BRCA1 mosaic mutation carrier do not necessarily have a milder phenotype compared to full heterozygotes. In this context our results implicate the importance of using highly sensitive sequencing platforms in routine diagnostics to ensure the detection of disease causing low-level mosaic mutations.
Citation Format: Bülow L, Keupp K, Richters L, Pohl E, Wappenschmidt B, Zarghooni V, Reichstein-Gnielinski S, Maringa M, Giesecke J, Rhiem K, Hahnen E, Schmutzler R. Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation – The origin of a constitutional mutation in a breast cancer family [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-09-03.
Collapse
Affiliation(s)
- L Bülow
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - K Keupp
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - L Richters
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - E Pohl
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - B Wappenschmidt
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - V Zarghooni
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - S Reichstein-Gnielinski
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - M Maringa
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - J Giesecke
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - K Rhiem
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - E Hahnen
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| | - R Schmutzler
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany
| |
Collapse
|
6
|
Keupp K, Richters L, Bülow L, Kröber S, Ernst C, Blümcke B, Versmold B, Waha A, Driesen J, Baasner A, Altmüller J, Thiele H, Nuernberg P, Wappenschmidt B, Neidhardt G, Rhiem K, Schmutzler R, Hahnen E, Hauke J. Abstract P3-08-01: TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: 24% of familial breast cancer (BC) and/or ovarian cancer (OC) cases analyzed within the framework of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) are due to pathogenic BRCA1/2 mutations. However, the mutation prevalence of non-BRCA1/2 genes associated with familial BC and/or BC/OC is largely unknown. Methods: Here, we present the first NGS data generated using the GC-HBOC-designed TruRisk® gene panel. In this study a cohort of 2028 BRCA1/2 and CHEK2 c.1100delC negative index cases was analyzed which comprises consecutive patients from BC families and BC/OC families complying the inclusion criteria of the GC-HBOC. Sequencing was performed on MiSeq, NextSeq, or HiSeq devices (Illumina) using customized SureSelect XT enrichment (Agilent). Data analysis was carried out using the SeqPilot software (version 4.2.2), SophiaDDM (Version 3.5.0.12-p5.0.0) as well as an in house bioinformatics pipeline (Cologne Center for Genomics, varpipe_v2.X). The analysis of copy number variations (CNV) based on NGS-data is currently in process and not yet included in the present mutation prevalence. Results: By focusing on 22 BC/OC associated genes (ATM, BARD1, BRIP1, CDH1, CHEK2, FAM175A, FANCM, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RINT1, STK11, TP53, XRCC2), we identified 71 different deleterious variants in 104 unrelated mutation carriers derived from 2028 BC and BC/OC families (8%). Interestingly, we identified a high prevalence of ATM mutations (n=29, 1.4%) in the familial cases. Additionally mutations in PALB2 (n=27), NBN (n=9), CHEK2 (n=14), BARD1 (n=9), BRIP1 (n=10), RAD51C (n=11) were frequently observed and we confirmed FANCM (n=17) as a novel BC predisposing gene. No mutations in MLH1, MRE11A, PTEN, RAD51D, STK11 and XRCC2 were identified in our collective. Conclusions: Due to the unexpectedly high mutation prevalence in familial cases, our study highlights the importance of these genes to be included in BC/OC routine diagnostics. In contrast we found low occurrence or absence of mutations for a subset of our gene selection which requires further investigation to optimize the gene panel for diagnostic purposes. Nevertheless this approach confirms the TruRisk® gene panel as a reliable tool for this comprehensive analysis.
Citation Format: Keupp K, Richters L, Bülow L, Kröber S, Ernst C, Blümcke B, Versmold B, Waha A, Driesen J, Baasner A, Altmüller J, Thiele H, Nuernberg P, Wappenschmidt B, Neidhardt G, Rhiem K, Schmutzler R, Hahnen E, Hauke J. TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-08-01.
Collapse
Affiliation(s)
- K Keupp
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - L Richters
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - L Bülow
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - S Kröber
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - C Ernst
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - B Blümcke
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - B Versmold
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - A Waha
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - J Driesen
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - A Baasner
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - J Altmüller
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - H Thiele
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - P Nuernberg
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - B Wappenschmidt
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - G Neidhardt
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - K Rhiem
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - R Schmutzler
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - E Hahnen
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| | - J Hauke
- Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Cologne, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany; Institute of Human Genetics; University of Cologne, Cologne, Germany
| |
Collapse
|
7
|
Keupp K, Kirfel J, Köhler J, Kröber S, Nürnberg P, Rhiem K, Wappenschmidt B, Schmutzler R. Prädiktive BRCA1/2-Gendiagnostik auf der Basis von Gewebeanalysen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
8
|
Herold N, Hauke J, Heimbach A, Richters L, Kröber S, Weber- Lassalle N, Pohl E, Wappenschmidt B, Neidhardt G, Rhiem K, Schmutzler R, Hahnen E. Erste Phänotypdaten für moderate Risikogene des TruRisk® Genpanels. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Paligo M, Aretini P, Kantala J, Aroer B, von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benítez J, Gilbert M, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HEJ, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AMW, Seynaeve C, van der Luijt RB, Devilee P, Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson OT, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J. Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer 2012; 106:2016-24. [PMID: 22669161 PMCID: PMC3388557 DOI: 10.1038/bjc.2012.160] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Revised: 03/18/2012] [Accepted: 03/25/2012] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase (MTHFR), both of which are important either directly or indirectly in maintaining genomic integrity. METHODS To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and 2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C>T (rs6917) polymorphism and the MTHFR 677 C>T (rs1801133) polymorphism, respectively. RESULTS There was no evidence of association between the PHB 1630 C>T and MTHFR 677 C>T polymorphisms with either disease for BRCA1 or BRCA2 mutation carriers when breast and ovarian cancer associations were evaluated separately. Analysis that evaluated associations for breast and ovarian cancer simultaneously showed some evidence that BRCA1 mutation carriers who had the rare homozygote genotype (TT) of the PHB 1630 C>T polymorphism were at increased risk of both breast and ovarian cancer (HR 1.50, 95%CI 1.10-2.04 and HR 2.16, 95%CI 1.24-3.76, respectively). However, there was no evidence of association under a multiplicative model for the effect of each minor allele. CONCLUSION The PHB 1630TT genotype may modify breast and ovarian cancer risks in BRCA1 mutation carriers. This association need to be evaluated in larger series of BRCA1 mutation carriers.
Collapse
Affiliation(s)
- A Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Whiley P, Walker LC, De LA Hoya M, Wappenschmidt B, Becker A, Blanco A, Blok MJ, Caligo MA, Chatfield C, Couch F, Diez O, Fachal L, Guidugli L, Enríquez S, Hansen T, Houdayer C, Imrie S, Lafferty A, Lázaro C, Menéndez M, Montagna M, Montalbán G, Santamariña M, Pederson I, Southey M, Tancredi M, Tenès A, Thomassen M, Van Overeem Vega A, Spurdle AB, Brown MA. A multi-centre international quality control study comparing mRNA splicing assay protocols and reporting practices from the ENIGMA consortium. Hered Cancer Clin Pract 2012. [PMCID: PMC3327263 DOI: 10.1186/1897-4287-10-s2-a87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
|
11
|
Becker A, Graeser M, Landwehr C, Hilger T, Baus W, Weber R, Wappenschmidt B, Schmutzler R. A functional assay for the identification of DNA double-strand break repair deficiency in heterozygous carriers of BRCA1/2 and RAD51C mutations. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Rhiem K, Gevensleben H, Wappenschmidt B, Warm M, Mallmann P, Schmutzler RK. Histopathologische Befunde in Präparaten prophylaktischer Mastektomien von BRCA1/2 Mutationsträgerinnen. Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1239009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Graeser M, Becker A, Wappenschmidt B, Landwehr C, Hilger T, Baus W, Weber R, Mallmann P, Schmutzler RK. Funktionelle Evaluation unklassifizierter Varianten in den Genen BRCA1 und BRCA2. Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1238954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Stoff-Khalili MA, Nedeljkovic-Kurepa A, Jung JS, Glover BV, Wappenschmidt B, Rhiem K, Bosse K, Mallmann P, Curiel DT, Schmutzler RK, Mathis MJ. Combination of oncolytic adenoviral therapy with chemotherapy for enhanced breast cancer cell killing. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2129
Oncolytic adenoviruses are emerging agents for treatment of cancer by tumor-restricted virus replication, cell lysis and virus spread. A promising oncolytic adenovirus agent, known as Ad5-24-RGD, harbors a 24-bp deletion in the E1A gene that abrogates the binding of E1A to the retinoblastoma tumor suppressor (Rb) and presents enhanced infectivity of primary cancer cells due to insertion of an Arg-Gly-Asp (RGD) motif into the fiber knob. Thus, Ad5-24-RGD has improved cancer cell infection efficiency due to expanded tropism toward alpha-v integrins. It also replicates selectively in cancer cells with Rb/p16 mutations. As with conventional therapy regimes, oncolytic virotherapy, by itself, has limited success in complete tumor eradication in both preclinical animal models and clinical studies. Combination of anticancer agents with different modes of action remains a mainstay in cancer treatment. We undertook one approach towards this end by combining oncolytic adenoviral therapy with chemotherapy. In this study, we investigated a combination treatment of breast cancer cells with Ad5-4-RGD and Docetaxel, a microtubule-stabilizing taxane that is being used in the clinic for the treatment of breast and prostate cancers and small cell carcinoma of the lung. Our results indicate a synergistic effect between Docetaxel and Ad5-24-RGD in breast cancer cell killing at a lower dose than either agent alone. These results suggest that viral replication was not inhibited by this chemotherapy treatment and that chemotherapy could reduce the amount of viral particles needed to help eradicate the tumor. Administration of lower viral loads would simultaneously improve safety and decrease immunogenicity of the vector. Likewise lower doses of chemotherapy agents would decrease toxicity and side effects. The inclusion of oncolytic adenoviruses into multimodal cancer treatment together with chemotherapy has a potential to become powerful therapeutic regimen.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2129.
Collapse
Affiliation(s)
- MA Stoff-Khalili
- 1 Hereditary Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
| | | | - JS Jung
- 2 LSU Health Sciences Center, LSU, Shreveport, LA
| | - BV Glover
- 2 LSU Health Sciences Center, LSU, Shreveport, LA
| | - B Wappenschmidt
- 1 Hereditary Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
| | - K Rhiem
- 1 Hereditary Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
| | - K Bosse
- 1 Hereditary Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
| | - P Mallmann
- 1 Hereditary Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
| | - DT Curiel
- 3 Division of Human Gene Therapy, University of Alabama at Birmingham, Birmingham
| | - RK Schmutzler
- 1 Hereditary Breast and Ovarian Cancer, University of Cologne, Cologne, Germany
| | - MJ Mathis
- 2 LSU Health Sciences Center, LSU, Shreveport, LA
| |
Collapse
|
15
|
Rhiem K, Fischer C, Lehnert M, Weinhold K, Wappenschmidt B, Schmutzler R. Erhöhtes Zervixkarzinom-Risiko in Hochrisikofamilien mit und ohne BRCA1/2 Mutation. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1089168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
16
|
Rhiem K, Fischer C, Bosse K, Wappenschmidt B, Schmutzler RK. Increased risk of cervical cancer in high-risk families with and without mutations in the BRCA1 and BRCA2 genes. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5588] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5588 Background: In BRCA germline mutation carriers increased risks for cancer at other sites than breast and ovary have been reported. Methods: To evaluate the risk of BRCA-associated cancers, we conducted a cross-section analysis in 4405 individuals from 409 families with BRCA1 (n=86) or BRCA2 mutations (n=53) and 270 high risk BRCA1/2 negative families ascertained by the Familial Breast and Ovarian Cancer Center Cologne. We considered proven mutation carriers, individuals affected by breast and ovarian cancer and their first degree relatives and identified 921 individuals from BRCA1 (604 female; 317 male), 571 from BRCA2 (365 female; 206 male) and 2913 from BRCA1/2 negative (1938 female; 975 male) families that suffered from 677 cancers other than breast and ovarian cancers. Relative risks (RR) of the study group compared to the general population were evaluated by the standardized incidence ratio (SIR), using data from two German Cancer Registries. Results: The risk for cervical cancer is significantly increased in women from BRCA1 and BRCA2 positive (RR=4.59, 95% CI=2.20 to 8.44, and RR=3.69, 95% CI=1.20 to 8.61; p=<0.001) and from BRCA1/2 negative families (RR=2.97, 95% CI=1.88 to 4.45). Moreover, the risk for pancreatic cancer in women from BRCA2 positive and BRCA1/2 negative families as well as the risk for prostate cancer in men from BRCA2 positive families is increased (RR=5.10, 95% CI=1.65 to 11.90; RR=1.98, 95% CI=1.02 to 3.46; RR=2.09; 95% CI=1.00 to 3.84). Conclusions: We here report an increased risk of cervical cancer for women from BRCA1 and BRCA2 positive and from BRCA1/2 negative high risk families, respectively. These results are in line with other studies in BRCA1 and 2 positive individuals and should be considered in the clinical risk management of these individuals. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Rhiem
- University of Cologne Medical School, Cologne, Germany; University of Heidelberg, Medical School, Heidelberg, Germany
| | - C. Fischer
- University of Cologne Medical School, Cologne, Germany; University of Heidelberg, Medical School, Heidelberg, Germany
| | - K. Bosse
- University of Cologne Medical School, Cologne, Germany; University of Heidelberg, Medical School, Heidelberg, Germany
| | - B. Wappenschmidt
- University of Cologne Medical School, Cologne, Germany; University of Heidelberg, Medical School, Heidelberg, Germany
| | - R. K. Schmutzler
- University of Cologne Medical School, Cologne, Germany; University of Heidelberg, Medical School, Heidelberg, Germany
| |
Collapse
|
17
|
Wappenschmidt B, Fimmers R, Brosig M, Meindl A, Schmutzler RK. Strategien und erste Ergebnisse zur Evaluierung unklassifizierter Varianten in den Genen BRCA1 und 2. Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
18
|
Rhiem K, Wappenschmidt B, Flucke U, Mallmann P, Schmutzler RK. Allelverlust-Analyse in BRCA-assoziierten Mamma- und Ovarialkarzinomen. Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
19
|
Bosse K, Gossmann A, Rhiem K, Wappenschmidt B, Mallmann P, Schmutzler R. Wachstumsrate des familiären Mammakarzinoms – wie engmaschig sollten die Vorsorgeintervalle sein? Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
20
|
Rhiem K, Wappenschmidt B, Flucke U, Bosse K, Mallmann P, Schmutzler RK. Molekulargenetische Charakterisierung assoziierter Tumoren bei BRCA1- und BRCA2-Familien. Geburtshilfe Frauenheilkd 2005. [DOI: 10.1055/s-2005-920835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
21
|
Wappenschmidt B, Fimmers R, Rhiem K, Brosig M, Wardelmann E, Meindl A, Arnold N, Mallmann P, Schmutzler RK. Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer. Breast Cancer Res 2005; 7:R775-9. [PMID: 16168123 PMCID: PMC1242149 DOI: 10.1186/bcr1291] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2004] [Revised: 05/26/2005] [Accepted: 06/30/2005] [Indexed: 11/25/2022] Open
Abstract
Introduction Unclassified variants (UVs) of unknown clinical significance are frequently detected in the BRCA2 gene. In this study, we have investigated the potential pathogenic relevance of the recurrent UV S384F (BRCA2, exon 10). Methods For co-segregation, four women from a large kindred (BN326) suffering from breast cancer were analysed. Moreover, paraffin-embedded tumours from two patients were analysed for loss of heterozygosity. Co-occurrence of the variant with a deleterious mutation was further determined in a large data set of 43,029 index cases. Nature and position of the UV and conservation among species were evaluated. Results We identified the unclassified variant S384F in three of the four breast cancer patients (the three were diagnosed at 41, 43 and 57 years of age). One woman with bilateral breast cancer (diagnosed at ages 32 and 50) did not carry the variant. Both tumours were heterozygous for the S384F variant, so loss of the wild-type allele could be excluded. Ser384 is not located in a region of functional importance and cross-species sequence comparison revealed incomplete conservation in the human, dog, rodent and chicken BRCA2 homologues. Overall, the variant was detected in 116 patients, five of which co-occurred with different deleterious mutations. The combined likelihood ratio of co-occurrence, co-segregation and loss of heterozygosity revealed a value of 1.4 × 10-8 in favour of neutrality of the variant. Conclusion Our data provide conclusive evidence that the S384F variant is not a disease causing mutation.
Collapse
Affiliation(s)
- B Wappenschmidt
- Department of Obstetrics and Gynaecology, University Hospital of Cologne, Cologne, Germany
| | - R Fimmers
- Institute of Medical Biometrics, Statistics and Epidemiology, University Hospital of Bonn, Bonn, Germany
| | - K Rhiem
- Department of Obstetrics and Gynaecology, University Hospital of Cologne, Cologne, Germany
| | - M Brosig
- Data Management of the German Consortium for Hereditary Breast and Ovarian Cancer at the Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - E Wardelmann
- Department of Pathology, University Hospital of Bonn, Bonn, Germany
| | - A Meindl
- Department of Obstetrics and Gynaecology, Technical University Hospital, Munich, Germany
| | - N Arnold
- Department of Obstetrics and Gynaecology, University Hospital of Kiel, Kiel, Germany
| | - P Mallmann
- Department of Obstetrics and Gynaecology, University Hospital of Cologne, Cologne, Germany
| | - RK Schmutzler
- Department of Obstetrics and Gynaecology, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
22
|
Frank B, Hemminki K, Wirtenberger M, Bermejo JL, Bugert P, Klaes R, Schmutzler RK, Wappenschmidt B, Bartram CR, Burwinkel B. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Breast Cancer Res 2005. [PMCID: PMC4233526 DOI: 10.1186/bcr1105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Burwinkel B, Wirtenberger M, Frank B, Klaes R, Schmutzler RK, Grzybowska E, Försti A, Bermejo JL, Bugert P, Wappenschmidt B, Butkiewicz D, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E, Bartram CR, Hemminki K. Association of NCOA3 (AIB1) polymorphisms with breast cancer risk. Breast Cancer Res 2005. [PMCID: PMC4233528 DOI: 10.1186/bcr1107] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
24
|
Wappenschmidt B, Wardelmann E, Gehrig A, Schöndorf T, Maass N, Bonatz G, Gassel AM, Pietsch T, Mallmann P, Weber BHF, Schmutzler RK. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas. Hum Pathol 2004; 35:1260-5. [PMID: 15492994 DOI: 10.1016/j.humpath.2004.06.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PTEN: and beta-catenin mutations constitute the predominant genetic alterations in endometrioid carcinomas of the endometrium. PTEN encodes a dual-specificity phosphatase with lipid phosphatase and protein tyrosine phosphatase activities that regulate both apoptosis and interactions with the extracellular matrix. Recent studies have associated PTEN mutations with tumorigenesis of prostate carcinoma via the Wnt signaling pathway, leading to nuclear beta-catenin accumulation. To elucidate the potential interaction of PTEN and beta-catenin in endometrial cancer, we performed mutation analyses of the entire PTEN gene and of exon 3 of the beta-catenin gene that is most frequently targeted by mutations. A total of 82 endometrial carcinomas comprising 62 type I endometrioid carcinomas and 20 type II high-grade carcinomas were investigated. In addition in a subset of 22 carcinomas, the intracellular beta-catenin distribution was analyzed by immunohistochemistry. Overall, 20 (24.4%) of 82 tumors revealed mutations in the PTEN gene, and 16 (19.5%) of 82, in the beta-catenin gene. Six tumors (7.3%) showed mutations in both the PTEN and beta-catenin gene. Mutations were mainly detected in endometrioid carcinomas of the endometrium. As expected, a striking nuclear accumulation of beta-catenin could be shown in tumors with beta-catenin mutations. In the vast majority of tumors with PTEN mutations, a regular staining pattern of the cytoplasmic and membranous compartments was found. We therefore conclude that, in contrast to prostate cancer, mutations in the PTEN gene seem not to affect cellular distribution of the beta-catenin protein in endometrial carcinomas.
Collapse
Affiliation(s)
- B Wappenschmidt
- Department of Obstetrics and Gynecology, University Hospitals, Cologne, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ulrich U, Wappenschmidt B, Wardelmann E, Mallmann P, Schmutzler R. PTEN- und β-Catenin-Mutationen treten gehäuft bei Frühformen des Endometriumkarzinoms auf. Geburtshilfe Frauenheilkd 2003. [DOI: 10.1055/s-2003-815189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
26
|
Hofmann W, Wappenschmidt B, Berhane S, Schmutzler R, Scherneck S. Detection of large rearrangements of exons 13 and 22 in the BRCA1 gene in German families. J Med Genet 2002; 39:E36. [PMID: 12114493 PMCID: PMC1735179 DOI: 10.1136/jmg.39.7.e36] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Schöndorf T, Becker M, Göhring UJ, Wappenschmidt B, Kolhagen H, Kurbacher CM. Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Anticancer Drugs 2001; 12:797-800. [PMID: 11707646 DOI: 10.1097/00001813-200111000-00002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Due to its pivotal role in signal transduction, the universal tumor suppressor PTEN (also termed MMAC or TEP) is one of the putative candidates for involvement in tumorigenesis of several tissues. Although involvement of PTEN in tumorigenesis was shown in different tissues, no data are available concerning PTEN activity in response to antineoplastic agents. Therefore, we assayed the PTEN activity exposed to either blank medium or the commonly used anti-cancer drugs cisplatin, adriamycin or paclitaxel, respectively, in three different concentrations. PTEN activity was determined using the Malachite Green assay basing upon dephosphorylation of phosphatidylinositol-3,4,5-triphosphate (PIP3) by the PTEN enzyme and subsequent determination of inorganic phosphate released. Although the three different anti-cancer drugs assayed act with different cellular modes, the antineoplastics influenced PTEN activity in a similar manner: at low concentrations tested all three antineoplastics significantly increased PTEN activity. However, increasing drug concentrations exhibited a decline but not a total loss of PTEN activity. The data indicate that PTEN activity is increased following cytotoxic drug exposure and, thereby, exhibits its suppressive function. However, the decrease of PTEN activity in response to increasing drug concentrations suggests an aberration of total functional activity. As far as the regulative checkpoint PTEN is abolished, tumor cells might evade cell death pathways resulting in increased proliferation of cancer cells. This might be a general event in refractory tumor cells surviving chemotherapy.
Collapse
Affiliation(s)
- T Schöndorf
- Department of Gynecology and Obstetics, University of Cologne, 50924 Cologne, Germany.
| | | | | | | | | | | |
Collapse
|
28
|
Wappenschmidt B, Golla A, Kempe A, Meindl A, Schmutzler RK. Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations. Breast Cancer Res 2001; 3. [PMCID: PMC3300581 DOI: 10.1186/bcr398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- B Wappenschmidt
- Department of Obstetrics and Gynecology, University of Bonn, Bonn, Germany
| | - A Golla
- Department of Medical Genetics, University of Munich, Munich, Gemany
| | - A Kempe
- Department of Obstetrics and Gynecology, University of Bonn, Bonn, Germany
| | - A Meindl
- Department of Medical Genetics, University of Munich, Munich, Gemany
| | - RK Schmutzler
- Department of Obstetrics and Gynecology, University of Bonn, Bonn, Germany
| | | |
Collapse
|
29
|
Freihoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler OD, von Deimling A, Schmutzler RK. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 1999; 79:754-8. [PMID: 10070865 PMCID: PMC2362671 DOI: 10.1038/sj.bjc.6690121] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
PTEN is a novel tumour-suppressor gene located on chromosomal band 10q23.3. This region displays frequent loss of heterozygosity (LOH) in a variety of human neoplasms including breast carcinomas. The detection of PTEN mutations in Cowden disease and in breast carcinoma cell lines suggests that PTEN may be involved in mammary carcinogenesis. We here report a mutational analysis of tumour specimens from 103 primary breast carcinomas and constitutive DNA from 25 breast cancer families. The entire coding region of PTEN was screened by single-strand conformation polymorphism (SSCP) analysis and direct sequencing using intron-based primers. No germline mutations could be identified in the breast cancer families and only one sporadic carcinoma carried a PTEN mutation at one allele. In addition, all sporadic tumours were analysed for homozygous deletions by differential polymerase chain reaction (PCR) and for allelic loss using the microsatellite markers D10S215, D10S564 and D10S573. No homozygous deletions were detected and only 10 out of 94 informative tumours showed allelic loss in the PTEN region. These results suggest that PTEN does not play a major role in breast cancer formation.
Collapse
Affiliation(s)
- D Freihoff
- Department of Obstetrics and Gynecology, University of Bonn Medical Center, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|